Generated June 2, 2026 at 8:33 PM ET
· Covers June 2 trading day
· 10 of 257 ready 8-Ks selected
· AI-assisted overview
The day featured several high-materiality events including Hub Group’s departure of its CFO and COO with a planned restatement filing by September, and Cingulate receiving a FDA Complete Response Letter for its ADHD drug due to CMC issues. Major M&A activity included KLX Energy Services acquiring Wolfpack assets for $17M, Chiron Real Estate closing a $249M senior housing acquisition, and John Wiley & Sons purchasing Emerald Publishing for $452M. Positive regulatory milestones included FDA approval of MannKind’s Afrezza for pediatric diabetes and Vera Therapeutics’ FDA alignment on an earlier eGFR analysis for atacipcept. Litigation news featured a court invalidating two Heron Therapeutics CINVANTI patents with an appeal planned, and Dragonfly Energy filing a trade libel suit over alleged false battery tests. Hycroft Mining released a technical report showing a $10B NPV at spot prices with a 51-year mine life.
leadership
negative
materiality 0.85
June 2, 2026, 4:55 PM ET
Hub Group CFO/COO depart; interim CFO hired; restatement filing targeted by Sept 14
- Kevin Beth (CFO/Treasurer) and Brian Meents (COO) departed on May 27, 2026.
- Todd Heeter appointed Interim CFO and Treasurer effective May 28, 2026; initial 6-month term with $125k/month consulting fee.
- Company expects to file restated financials (2023-2025) and Q1 2026 10-Q by September 14, 2026.
regulatory
negative
materiality 0.85
June 2, 2026, 8:10 AM ET
Cingulate receives FDA Complete Response Letter for CTx-1301; no safety/efficacy issues, CMC-only
- FDA issued a Complete Response Letter for CTx-1301 (dexmethylphenidate HCl) NDA for ADHD.
- No current concerns about clinical safety or efficacy; CMC information requests identified.
- Company expects prompt resubmission of requested CMC data; has ~$30M cash on hand.
KLXE
KLX Energy Services Holdings, Inc.
M&A
positive
materiality 0.85
June 2, 2026, 5:14 PM ET
KLX Energy acquires Wolfpack assets for $17M; also exchanges $2.19M notes for equity
- Purchase price $17M: $14M cash at closing plus two $1.5M deferred payments (cash or KLX stock).
- Wolfpack 2025 revenue $38.2M, Adjusted EBITDA $5.8M; deal immediately accretive with $2M+ expected annual synergies.
- Acquired ~350 accommodations trailers, 14 proprietary water filtration systems with exclusive IP rights.
XRN
Chiron Real Estate Inc.
M&A
positive
materiality 0.85
June 2, 2026, 4:30 PM ET
Chiron Real Estate closes $249M acquisition of two senior housing communities; issues $100M Series C preferred
- Acquired The Landing Alexandria ($130M) and The Riviera Alexandria ($118.9M) on June 1, 2026.
- Funded with $100M Series C Preferred Stock private placement and $147M additional Credit Facility borrowings.
- Issued 1,000,000 shares of 6.00% Series C Convertible Preferred Stock at $100/share to four institutional investors.
WLY
JOHN WILEY & SONS, INC.
M&A
positive
materiality 0.85
June 2, 2026, 8:30 AM ET
Wiley acquires Emerald Publishing for $452M; adds ~500 journals, expected accretive in year one
- Purchase price of £337.5M (~$452M) all-cash; funded from cash on hand.
- Emerald generates >$85M revenue, 92% recurring, mid-single-digit growth.
- Expected accretive to adjusted EPS in year one; ~7x EV/EBITDA including ~$30M cost synergies by year three.
regulatory
positive
materiality 0.75
June 2, 2026, 8:00 AM ET
FDA approves Afrezza for pediatric diabetes patients ages 6+
- FDA approved supplemental BLA for Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes.
- More than 350,000 U.S. children and adolescents live with diabetes; majority have type 1 and require lifelong insulin.
- Approval fulfills the last postmarketing requirement from the original June 27, 2014 approval letter.
VERA
Vera Therapeutics, Inc.
regulatory
positive
materiality 0.75
June 2, 2026, 7:05 AM ET
Vera Therapeutics announces FDA alignment on earlier eGFR analysis for atacicept; results expected Q3 2026
- FDA agreed to revised ORIGIN 3 eGFR analysis plan to support potential full approval of atacicept in IgA Nephropathy.
- eGFR results now expected in the third quarter of 2026.
- Company plans to submit supplemental Biologics License Application for full approval in Q4 2026.
HRTX
HERON THERAPEUTICS, INC. /DE/
litigation
negative
materiality 0.75
June 2, 2026, 5:15 PM ET
Court invalidates two CINVANTI patents; Heron to appeal to Federal Circuit
- U.S. District Court for Delaware ruled claims of Patents 12,115,255 and 12,290,520 invalid on June 1, 2026.
- Decision does not affect prior settlements for CINVANTI or APONVIE injectable emulsions.
- Heron intends to appeal to the Federal Circuit, a court specializing in patent disputes.
DFLI
Dragonfly Energy Holdings Corp.
litigation
negative
materiality 0.55
June 2, 2026, 7:45 AM ET
Dragonfly Energy files trade libel suit over alleged false battery tests
- Lawsuit filed June 1, 2026 in Nevada state court against William Errol Prowse IV and Prowse Publications LLC.
- Alleges Prowse removed structural components and used damaged batteries in tests, then published false statements.
- Seeks damages and injunctive relief for financial and reputational harm to Battle Born Batteries brand.
HYMC
HYCROFT MINING HOLDING CORP
other material
positive
materiality 0.85
June 2, 2026, 4:31 PM ET
Hycroft TRS shows $10B NPV at spot; 51-year mine life with 10.4M oz gold
- Base case post-tax NPV5 of $4.3B and IRR 16.9%; spot price post-tax NPV5 $10.0B with IRR 30.1%.
- 51-year mine plan averaging 295k AuEq oz/yr; first 10 years average >330k AuEq oz/yr.
- LOM production: 10.4M oz gold and 347.5M oz silver; initial capex $2.4B, sustaining $3.1B.